Tissue factor in cardiovascular diseases - Molecular mechanisms and clinical implications

Review

关键词: SMOOTH-MUSCLE-CELLS;    FACTOR PATHWAY INHIBITOR;    HUMAN-ENDOTHELIAL-CELLS;    ACUTE MYOCARDIAL-INFARCTION;    MONOCYTE CHEMOATTRACTANT PROTEIN-1;    PLASMINOGEN-ACTIVATOR INHIBITOR-1;    HUMAN ATHEROSCLEROTIC PLAQUES;    FACTOR PROCOAGULANT ACTIVITY;    ACUTE CORONARY SYNDROMES;    C-REACTIVE PROTEIN;   

DOI  :  10.1161/CIRCULATIONAHA.105.567297

来源: SCIE

【 摘 要 】

Tissue factor (TF), formerly known as thromboplastin, is the key initiator of the coagulation cascade; it binds factor VIIa resulting in activation of factor IX and factor X, ultimately leading to fibrin formation. TF expression and activity can be induced in endothelial cells, vascular smooth muscle cells, and monocytes by various stimuli such as cytokines, growth factors, and biogenic amines. These mediators act through diverse signal transduction mechanisms including MAP kinases, PI3-kinase, and protein kinase C. Cellular TF is present in three pools as surface, encrypted, and intracellular protein. TF can also be detected in the bloodstream, referred to as circulating or blood-borne TF. Elevated levels of TF are observed in patients with cardiovascular risk factors such as hypertension, diabetes, dyslipidemia, and smoking as well as in those with acute coronary syndromes. TF may indeed be involved in the pathogenesis of atherosclerosis by promoting thrombus formation; in addition, it can induce migration and proliferation of vascular smooth muscle cells. As a consequence, therapeutic strategies have been developed to specifically interfere with the action of TF such as antibodies against TF, site-inactivated factor VIIa, or recombinant TF pathway inhibitor. Inhibition of TF action appears to be an attractive target for the treatment of cardiovascular diseases.

【 授权许可】

Free